Association between Atherogenic Dyslipidemia and Subclinical Myocardial Injury in the General Population

Nada S Elbadawi1, Moaze H Sobih1, Mai Z Soliman2

  • 1Epidemiological Cardiology Research Center (EPICARE), Department of Medicine, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

PubMed

Insights

Atherogenic dyslipidemia, characterized by high triglycerides and low HDL cholesterol, significantly increases the risk of subclinical myocardial injury. This finding underscores the importance of addressing lipid profiles for cardiovascular disease prevention.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Lipid Metabolism

Background:

  • Subclinical myocardial injury (SCMI) is a predictor of adverse cardiovascular disease (CVD) outcomes.
  • Identifying risk factors for SCMI is crucial for CVD prevention and management.
  • Atherogenic dyslipidemia, defined by high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C), is a potential risk factor for SCMI.

Purpose of the Study:

  • To investigate the association between atherogenic dyslipidemia and SCMI.
  • To examine the relationship between different lipid profiles (TG and HDL-C combinations) and SCMI risk.

Main Methods:

  • Analysis of 7093 participants from the National Health and Nutrition Examination Survey (NHANES-III).
  • Atherogenic dyslipidemia defined as TG ≥ 150 mg/dL and HDL-C < 40 mg/dL (men) or <50 mg/dL (women).
  • SCMI assessed using a cardiac infarction injury score (CIIS) ≥ 10 on electrocardiography; multivariable logistic regression used for analysis.

Main Results:

  • 22.5% of participants had atherogenic dyslipidemia, and 26.3% had SCMI.
  • Atherogenic dyslipidemia was linked to a higher prevalence of SCMI (31.2% vs. 23.9%, p < 0.001) compared to normal lipid profiles.
  • Multivariable analysis showed atherogenic dyslipidemia had the highest odds of SCMI (OR: 1.31, 95% CI: 1.14-1.52).

Conclusions:

  • Atherogenic dyslipidemia is significantly associated with an increased risk of SCMI.
  • These findings highlight the role of lipid abnormalities beyond traditional risk factors in subclinical CVD development.
  • Targeting atherogenic dyslipidemia may be important for SCMI prevention strategies.

Related Concept Videos

Inflammation01:38

Inflammation

Overview
53.2K
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
27
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
140
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
119
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
68